| 摘要 |
<p>Patients suffering from Alhzheimer's disease are treated by transdermally administering an effective amount of propentofylline in the form of an occlusive device containing a delivery composition comprising a carrier vehicle having uniformly distributed therein effective amounst of propentofylline and, optionally, a penetration enhancer. The occlusive device may be a matrix type patch in which the carrier vehicle is a pressure sensitive adhesive or a reservoir type patch in which the carrier vehicle is a liquid of controlled viscosity, i.e. a gel, wherein the reservoir system contains means for maintaining it in a propentofylline transferring relationship with the derma when applied. Daily dosages of between about 5 and 49 mg/day are sufficient to maintain adequate plasma propentofylline levels.</p> |
